Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 13/20 | 0.60 |
| ▸ | AR | P10275 | 3/20 | 0.59 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4176289 | 1.00 | SRD5A1 (0.60) | SRD5A1ARSRD5A2 | |
| SCHEMBL4184512 | 0.92 | SRD5A1 (0.62) | SRD5A1ARSRD5A2 | |
| SCHEMBL4184510 | 0.92 | SRD5A1 (0.62) | SRD5A1ARSRD5A2 | |
| SCHEMBL4174717 | 0.91 | AR (0.60) | SRD5A1ARSRD5A2 | |
| SCHEMBL4174715 | 0.91 | AR (0.60) | SRD5A1ARSRD5A2 | |
| SCHEMBL14504060 | 0.90 | SRD5A1 (0.60) | SRD5A1ARSRD5A2 | |
| SCHEMBL4177467 | 0.89 | AR (0.76) | SRD5A1ARSRD5A2 | |
| SCHEMBL4177468 | 0.89 | AR (0.76) | SRD5A1ARSRD5A2 | |
| SCHEMBL13611358 | 0.89 | AR (0.76) | SRD5A1ARSRD5A2 | |
| SCHEMBL13604057 | 0.89 | AR (0.76) | SRD5A1ARSRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082320-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2009-03-26 | — | — | US | claimed |
| US-20070088042-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MEISSNER ROBERT S | 2007-04-19 | — | — | US | claimed |
| US-7186838-B2 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | claimed |
| US-20050165039-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-07-28 | — | — | US | claimed |
| US-7625920-B2 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090082320-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2009-03-26 | — | — | US | disclosed |
| US-20070088042-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MEISSNER ROBERT S | 2007-04-19 | — | — | US | disclosed |
| US-7186838-B2 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050165039-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165039-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | FSHR, AR, NR5A1 | SRD5A1 8/4885AR 2/4885SRD5A2 12/4885 |
| US-20070088042-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | FSHR, AR, NR5A1 | SRD5A1 8/4885AR 2/4885SRD5A2 12/4885 |
| US-20090082320-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | FSHR, AR, NR5A1 | SRD5A1 8/4885AR 2/4885SRD5A2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.